摘要
目的探讨缬沙坦联合氨氯地平对高血压病患者血栓前状态的影响。方法选取我院就诊的高血压病患者400例,随机分为四组,分别给予缬沙坦/氨氯地平80mg/5mg.qd(A组);缬沙坦胶囊80mg.qd(B组);氨氯地平片5mg.qd(C组);对照组安慰剂(D组)。采用双抗体夹心酶联免疫吸附法、发色底物法及Born比浊法,观察两组患者血浆中血管内假血友病因子(Von Willebrand's factor,vWF)、血小板α糖蛋白-140(granulemembrane protein 140,GMP-140)、D-二聚体(D-Dimer)、纤溶酶原激活物抑制物(plasminogen acti-vator inhibitor,PAI)的变化。结果对照组D组vWF、GMP-140、D-Dimer、PAI治疗前后其差别无统计学意义(P<0.05);A、B、C组以上指标治疗后较治疗前均显著下降(P<0.05),其中A组下降最为显著(P<0.05),BC组降幅差别无统计学意义。结论缬沙坦/氨氯地平可预防高血压病患者血栓前状态的形成,其效果优于缬沙坦或氨氯地平单一治疗。
【Objective】 To investigate the ettect of valsartan and amlodipine on on Prethrombotic State（PTS） with essential hypertension.【Methods】 400 patients were randomly divided into four groups： valsartan / amlodipine group（A group）,valsartan group（B group）,amlodipine group（C group）,and control group.With enzyme linked immunosorbent assay,chromogenic substances assay and furbidimetry assay,The levels of Von Willebrand＇s factor（vWF）,granulemembrane protein 140（GMP-140）、D-Dimer and plasminogen activator inhibitor（PAI）were measured before and after treated.【Results】 In ABC groups,the plasma levels of vWF、 GMP-140、D-Dimer、PAI and PAG were decreased significantly after 8 weeks treatment.The decreased levels of A group were more higher than the B、C groups.In control group,the levels of those markers were no statistical significance.【Conclusion】 Both valsartan and amlodipine can inhibit PTS in patients with essential hypertension,and valsartan combined amlodipine achives better results.
出处
《中国医学工程》
2011年第10期9-11,共3页
China Medical Engineering
关键词
缬沙坦/氨氯地平
血栓前状态
高血压病
valsartan/amlodipine
prethrombotic state
essential hypertension
